Plain-English translation of NCT06951867 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether , a newer biologic medication approved to treat severe asthma, may be linked to serious heart problems. This is an observational study, meaning researchers will review existing medical records from patients across multiple countries rather than asking you to take any new medication or attend visits. The study compares heart safety outcomes between people taking this medication and those receiving standard asthma treatments.
When the medication was tested in clinical trials, doctors noticed a small increase in heart-related side effects in some patients taking the treatment compared to those on placebo. Health regulators want to understand whether this pattern continues as more patients use this medication in real-world settings and over longer periods of time.
You likely qualify if…
You likely don't qualify if…
You would not need to attend any clinic visits or take any new medication. Researchers will gather information from your existing medical records from your doctors and hospitals across Denmark, France, Germany, or the United States. The study will follow your health records for approximately five years to track whether you experience any serious heart-related events and compare outcomes between people taking the new treatment and those receiving standard care.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Denmark
France
Germany
Sponsor
AstraZeneca
Collaborators
IQVIA Pvt. Ltd
Enrollment target
~16,640 participants
Started
September 2025
Primary completion
May 2029
Age range
12 Years – 130 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
AstraZeneca Clinical Study Information Center
IQVIA Pty Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.